PT4268843T - Anticorpos contra il-6 melhorados - Google Patents

Anticorpos contra il-6 melhorados

Info

Publication number
PT4268843T
PT4268843T PT231893850T PT23189385T PT4268843T PT 4268843 T PT4268843 T PT 4268843T PT 231893850 T PT231893850 T PT 231893850T PT 23189385 T PT23189385 T PT 23189385T PT 4268843 T PT4268843 T PT 4268843T
Authority
PT
Portugal
Prior art keywords
antibodies
improved
Prior art date
Application number
PT231893850T
Other languages
English (en)
Portuguese (pt)
Original Assignee
F Hoffmann La Roche Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche Ltd filed Critical F Hoffmann La Roche Ltd
Publication of PT4268843T publication Critical patent/PT4268843T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT231893850T 2014-11-07 2015-11-06 Anticorpos contra il-6 melhorados PT4268843T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US201562247705P 2015-10-28 2015-10-28

Publications (1)

Publication Number Publication Date
PT4268843T true PT4268843T (pt) 2025-10-31

Family

ID=54602042

Family Applications (2)

Application Number Title Priority Date Filing Date
PT231893850T PT4268843T (pt) 2014-11-07 2015-11-06 Anticorpos contra il-6 melhorados
PT157975384T PT3215530T (pt) 2014-11-07 2015-11-06 Anticorpos de il-6 melhorados

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT157975384T PT3215530T (pt) 2014-11-07 2015-11-06 Anticorpos de il-6 melhorados

Country Status (32)

Country Link
US (3) US11142571B2 (cg-RX-API-DMAC7.html)
EP (3) EP3632931A1 (cg-RX-API-DMAC7.html)
JP (1) JP6594438B2 (cg-RX-API-DMAC7.html)
KR (2) KR102636726B1 (cg-RX-API-DMAC7.html)
CN (1) CN107249631B (cg-RX-API-DMAC7.html)
AU (1) AU2015342882B2 (cg-RX-API-DMAC7.html)
CA (1) CA2965689C (cg-RX-API-DMAC7.html)
CL (1) CL2017001135A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017005404A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170231A (cg-RX-API-DMAC7.html)
DK (2) DK4268843T3 (cg-RX-API-DMAC7.html)
EA (1) EA035199B1 (cg-RX-API-DMAC7.html)
ES (1) ES2756275T3 (cg-RX-API-DMAC7.html)
FI (1) FI4268843T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20251312T1 (cg-RX-API-DMAC7.html)
HU (1) HUE046181T2 (cg-RX-API-DMAC7.html)
IL (1) IL251858B (cg-RX-API-DMAC7.html)
LT (1) LT4268843T (cg-RX-API-DMAC7.html)
MA (1) MA51554A (cg-RX-API-DMAC7.html)
MX (2) MX385206B (cg-RX-API-DMAC7.html)
MY (1) MY185114A (cg-RX-API-DMAC7.html)
PE (1) PE20171107A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500809B1 (cg-RX-API-DMAC7.html)
PL (2) PL3215530T3 (cg-RX-API-DMAC7.html)
PT (2) PT4268843T (cg-RX-API-DMAC7.html)
RS (2) RS67353B1 (cg-RX-API-DMAC7.html)
SA (1) SA517381458B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201703574VA (cg-RX-API-DMAC7.html)
SI (1) SI3215530T1 (cg-RX-API-DMAC7.html)
UA (1) UA122673C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016073890A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201702985B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2763916C2 (ru) 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
JP2019510078A (ja) * 2016-02-23 2019-04-11 セセン バイオ, インコーポレイテッド Il−6アンタゴニスト製剤およびその使用
CN110291108A (zh) * 2016-12-19 2019-09-27 格兰马克药品股份有限公司 新型tnfr激动剂及其用途
AU2018237359B2 (en) 2017-03-22 2024-06-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
AR111190A1 (es) 2017-03-22 2019-06-12 Genentech Inc Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
TW202144410A (zh) 2020-03-13 2021-12-01 美商建南德克公司 抗介白素-33抗體及其用途
EP4126949A1 (en) 2020-03-24 2023-02-08 Genentech, Inc. Tie2-binding agents and methods of use
EP4228706A1 (en) 2020-10-15 2023-08-23 Genentech, Inc. Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
CN116554298A (zh) * 2022-02-25 2023-08-08 南京工业大学 一种强化细菌卷曲菌毛提高人表皮生长因子分泌生产效率的方法
CN115343483B (zh) * 2022-08-12 2024-11-26 苏州邦器生物技术有限公司 一种自身免疫性糖尿病检测用试剂盒及其制备方法
CA3264497A1 (en) * 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (cg-RX-API-DMAC7.html) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック,インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
CA2466034C (en) 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
CN1658836A (zh) 2002-05-07 2005-08-24 控制传输系统公司 形成药物传递装置的方法
CA2506230A1 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2009521909A (ja) * 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング IL−6とIL−6Rαの複合体のgp130への結合を阻害する抗IL−6抗体
EP2004690A2 (en) 2006-03-13 2008-12-24 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008045140A1 (en) 2006-05-19 2008-04-17 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
KR101829776B1 (ko) * 2007-05-21 2018-02-19 앨더바이오 홀딩스 엘엘씨 Il-6에 대한 항체 및 이의 용도
KR20160005378A (ko) 2007-09-14 2016-01-14 사노피 파스테르 바이오로직스, 엘엘씨 클로스트리듐 디피실리 톡소이드 a 및 b를 포함하는 약학적 조성물
EA201000844A1 (ru) 2007-11-21 2011-10-31 Амген Инк. Связывающие wise агенты и эпитопы
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
RU2537139C2 (ru) 2008-01-15 2014-12-27 Эбботт Гмбх Унд Ко.Кг Порошковые белковые композиции и способы их получения
HUE026179T2 (en) 2008-08-05 2016-05-30 Novartis Ag Preparations and methods for antibodies against complement C5 protein
EP2324930B1 (en) 2008-09-12 2012-11-14 KDF Co., Ltd. Water-spouting device
WO2010039750A2 (en) 2008-10-01 2010-04-08 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
KR20110091777A (ko) 2008-11-26 2011-08-12 글락소 그룹 리미티드 폴리펩티드, 항체 가변 도메인 및 길항제
US20120034212A1 (en) 2009-01-29 2012-02-09 Michael Bowen Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CA2804185C (en) 2010-07-12 2017-03-21 Covx Technologies Ireland Limited Multifunctional antibody conjugates
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US20150239970A1 (en) 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
SG11201510315TA (en) 2013-07-12 2016-01-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
MX385206B (es) 2025-03-14
CA2965689A1 (en) 2016-05-12
PL3215530T3 (pl) 2020-05-18
PH12017500809B1 (en) 2023-09-20
AU2015342882B2 (en) 2021-05-20
MA51554A (fr) 2020-11-18
FI4268843T3 (fi) 2025-11-14
RS59805B1 (sr) 2020-02-28
CN107249631B (zh) 2021-11-23
AU2015342882A1 (en) 2017-05-18
EA201791005A1 (ru) 2017-09-29
ZA201702985B (en) 2019-10-30
EP3215530B9 (en) 2020-09-09
EP3215530B1 (en) 2019-08-21
SG10202103420PA (en) 2021-05-28
ES2756275T3 (es) 2020-04-27
KR102770849B1 (ko) 2025-02-20
EP4268843A3 (en) 2023-12-27
PT3215530T (pt) 2019-11-21
PH12017500809A1 (en) 2017-10-02
NZ731090A (en) 2024-03-22
JP2017535285A (ja) 2017-11-30
EA035199B1 (ru) 2020-05-14
UA122673C2 (uk) 2020-12-28
CO2017005404A2 (es) 2017-10-31
JP6594438B2 (ja) 2019-10-23
MY185114A (en) 2021-04-30
US20250059270A1 (en) 2025-02-20
KR20240023450A (ko) 2024-02-21
WO2016073890A1 (en) 2016-05-12
KR102636726B1 (ko) 2024-02-13
HRP20191945T1 (hr) 2020-01-24
CN107249631A (zh) 2017-10-13
US20220169719A1 (en) 2022-06-02
CR20170231A (es) 2017-09-25
CL2017001135A1 (es) 2017-12-15
EP3632931A1 (en) 2020-04-08
HUE046181T2 (hu) 2020-02-28
ES2756275T9 (es) 2020-10-29
SA517381458B1 (ar) 2020-07-09
KR20170077196A (ko) 2017-07-05
DK4268843T3 (da) 2025-11-10
IL251858A0 (en) 2017-06-29
BR112017008672A2 (pt) 2018-03-20
US11142571B2 (en) 2021-10-12
SG11201703574VA (en) 2017-05-30
US20190194312A1 (en) 2019-06-27
RS67353B1 (sr) 2025-11-28
PE20171107A1 (es) 2017-08-07
PL4268843T3 (pl) 2025-12-15
IL251858B (en) 2022-09-01
CA2965689C (en) 2022-03-22
LT4268843T (lt) 2025-11-25
DK3215530T3 (da) 2019-11-25
MX2017005992A (es) 2017-09-15
HK1244008A1 (en) 2018-07-27
MX2021008663A (es) 2021-08-19
EP4268843B1 (en) 2025-09-03
EP4268843A2 (en) 2023-11-01
SI3215530T1 (sl) 2020-02-28
HRP20251312T1 (hr) 2025-12-05
EP3215530A1 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
IL250583A0 (en) Anti-tigit antibodies
IL252004A0 (en) Ether-substituted antibody
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
IL252422A0 (en) Effector-deficient anti-cd32a antibodies
ZA201702985B (en) Improved il-6 antibodies
GB201508180D0 (en) Antibodies
GB201410520D0 (en) Antibody
ZA201604640B (en) Novel anti-netrin-1 antibody
IL250374A0 (en) Antibodies against ceramide
IL248220A0 (en) Anti- nme antibody
SG11201700922YA (en) Anti-orai1 antibody
SI3628731T1 (sl) Novo protitelo proti presepsinu
GB201509907D0 (en) Antibodies
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies
GB201405775D0 (en) Antibodies
GB201401200D0 (en) Antibodies
GB201508437D0 (en) Antibodies
GB201508444D0 (en) Antibodies
GB201507541D0 (en) Antibodies
GB201504858D0 (en) Antibodies
GB201418776D0 (en) Antibody